Farmers & Merchants Trust Co of Chambersburg PA lessened its position in shares of Amgen, Inc. (NASDAQ:AMGN) by 34.5% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 475 shares of the medical research company’s stock after selling 250 shares during the period. Farmers & Merchants Trust Co of Chambersburg PA’s holdings in Amgen were worth $88,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently modified their holdings of the company. Capital Financial Planning LLC bought a new position in Amgen in the 4th quarter valued at approximately $27,000. Next Capital Management LLC bought a new position in shares of Amgen during the fourth quarter valued at $33,000. Arbor Wealth Management LLC raised its stake in shares of Amgen by 154.5% during the second quarter. Arbor Wealth Management LLC now owns 168 shares of the medical research company’s stock valued at $31,000 after acquiring an additional 102 shares during the last quarter. Clarfeld Financial Advisors LLC bought a new position in shares of Amgen during the fourth quarter valued at $41,000. Finally, C J Advisory Inc bought a new position in shares of Amgen during the first quarter valued at $40,000. 77.50% of the stock is owned by institutional investors.

Shares of AMGN traded up $0.03 during trading hours on Tuesday, hitting $176.11. 478,007 shares of the stock were exchanged, compared to its average volume of 2,373,673. Amgen, Inc. has a fifty-two week low of $166.30 and a fifty-two week high of $210.19. The company has a quick ratio of 2.53, a current ratio of 2.77 and a debt-to-equity ratio of 2.71. The business’s 50-day simple moving average is $180.28. The company has a market capitalization of $106.95 billion, a price-to-earnings ratio of 12.23, a P/E/G ratio of 2.14 and a beta of 1.16.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Tuesday, April 30th. The medical research company reported $3.56 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $3.45 by $0.11. The company had revenue of $5.56 billion during the quarter, compared to analysts’ expectations of $5.55 billion. Amgen had a net margin of 34.00% and a return on equity of 71.02%. Amgen’s revenue for the quarter was up .1% compared to the same quarter last year. During the same period in the prior year, the company posted $3.47 earnings per share. As a group, equities analysts anticipate that Amgen, Inc. will post 13.89 earnings per share for the current year.

Several equities analysts have recently issued reports on the stock. Zacks Investment Research raised shares of GreenTree Hospitality Group from a “sell” rating to a “hold” rating in a research note on Monday, April 15th. Citigroup raised shares of Gilead Sciences from a “neutral” rating to a “buy” rating and set a $66.80 price target for the company in a research note on Wednesday, May 22nd. BidaskClub raised shares of Westport Fuel Systems from a “hold” rating to a “buy” rating in a research note on Friday, July 12th. Oppenheimer set a $210.00 price target on shares of Amgen and gave the company a “buy” rating in a research note on Friday, May 24th. Finally, Cantor Fitzgerald reaffirmed a “hold” rating and set a $41.00 price target on shares of Mylan in a research note on Monday, April 1st. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and ten have given a buy rating to the company’s stock. Amgen presently has a consensus rating of “Hold” and an average price target of $208.00.

In other Amgen news, Director Ronald D. Sugar sold 2,000 shares of the firm’s stock in a transaction on Wednesday, June 5th. The shares were sold at an average price of $175.68, for a total value of $351,360.00. Following the completion of the sale, the director now directly owns 16,219 shares in the company, valued at $2,849,353.92. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold 6,000 shares of company stock valued at $1,077,980 over the last 90 days. Corporate insiders own 0.25% of the company’s stock.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.

See Also: Return on Equity (ROE)

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.